RxDoctor Payments Data

Parinaz Neshati, MD

Family Medicine · Houston, TXNPI 1225534274

Payments from drug & device makers

$576in general payments, 2019–2025

Across 17 payments — averaging $33.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$205
  • AbbVie$88
  • Teva Pharmaceuticals USA, Inc.$85
  • Pfizer$56
  • Lilly USA, LLC$53
  • Hologic Sales And Service, LLC$42
  • plus $47 from 3 others

What the payments were for

  • Food & beverage$576100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$576 in reported general payments places this provider in the 50th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$25,979
Medicare patients
71
Services billed
402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide50$46,134
MounjaroTirzepatide14$14,580
JanumetSitagliptin Phos/Metformin Hcl11$13,433
Rosuvastatin Calcium80$1,617
Diclofenac Sodium24$896
Valsartan16$653
Omeprazole46$496
Atorvastatin Calcium93$493
Alendronate Sodium53$478
Losartan Potassium37$379
Gabapentin21$294
Albuterol Sulfate HfaAlbuterol Sulfate11$293
Levothyroxine Sodium38$289
Azelastine Hcl18$287
Metformin Hcl ErMetformin Hcl26$278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$205$46,13450 claims
Lilly USA, LLCMounjaro$53$14,58014 claims
MerckJanumet$12$13,43311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →